Biomedical research at Oslo University Hospital
Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.
Click here to see hierarchical division and subunit overview
Summary of publications:
Publications (original articles or review articles) published in 2016 from OUS - Section for Cellular Therapy
11 publications found
Enhancing Antitumor Immune Responses by Optimized Combinations of Cell-penetrating Peptide-based Vaccines and Adjuvants
Mol Ther, 24 (9), 1675-85
DOI 10.1038/mt.2016.134, PubMed 27377043
Cancer immunotherapy: from the lab to clinical applications-Potential impact on cancer centres' organisation
Ecancermedicalscience, 10, 691
DOI 10.3332/ecancer.2016.691, PubMed 27994647
Non-small cell lung cancer is characterised by a distinct inflammatory signature in serum compared with chronic obstructive pulmonary disease
Clin Transl Immunology, 5 (11), e109
DOI 10.1038/cti.2016.65, PubMed 27990285
Dentate gyrus-cornu ammonis (CA) 4 volume is decreased and associated with depressive episodes and lipid peroxidation in bipolar II disorder: Longitudinal and cross-sectional analyses
Bipolar Disord, 18 (8), 657-668
DOI 10.1111/bdi.12457, PubMed 27995733
T-helper cell receptors from long-term survivors after telomerase cancer vaccination for use in adoptive cell therapy
Oncoimmunology, 5 (12), e1249090
DOI 10.1080/2162402X.2016.1249090, PubMed 28123886
Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells
Oncoimmunology, 5 (11), e1232237
DOI 10.1080/2162402X.2016.1232237, PubMed 27999747
MtDNA depleted PC3 cells exhibit Warburg effect and cancer stem cell features
Oncotarget, 7 (26), 40297-40313
DOI 10.18632/oncotarget.9610, PubMed 27248169
Targeting B-cell neoplasia with T-cell receptors recognizing a CD20-derived peptide on patient-specific HLA
Oncoimmunology, 5 (5), e1138199
DOI 10.1080/2162402X.2016.1138199, PubMed 27467957
Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling
Blood, 129 (6), 759-770
DOI 10.1182/blood-2016-05-718494, PubMed 28011673
Cost and clinical outcome of islet transplantation in Norway 2010-2015
Clin Transplant, 31 (1)
DOI 10.1111/ctr.12871, PubMed 27862341
Diversification of Antitumour Immunity in a Patient with Metastatic Melanoma Treated with Ipilimumab and an IDO-Silenced Dendritic Cell Vaccine
Case Rep Med, 2016, 9639585
DOI 10.1155/2016/9639585, PubMed 27504122